We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.91B
1-Year Est. Return 304.52%
This Fund
S&P 500
This Quarter Est. Return
+56.08%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$2.97B
AUM Growth
+$504M
Cap. Flow
-$339M
Cap. Flow %
-11.43%
Top 10 Hldgs %
62.79%
Holding
48
New
2
Increased
8
Reduced
8
Closed
7

Top Buys

Rank Stock Value
1
XNCR icon
Xencor
XNCR
+$65.6M
2
IRON icon
Disc Medicine
IRON
+$54.9M
3
IVVD icon
Invivyd
IVVD
+$40.6M
4
STOK icon
Stoke Therapeutics
STOK
+$18.3M
5
CBIO
Crescent Biopharma
CBIO
+$17.3M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$170M
2
CDTX
Cidara Therapeutics
CDTX
+$135M
3
AXSM icon
Axsome Therapeutics
AXSM
+$61.6M
4
SEPN
Septerna Inc
SEPN
+$54.8M
5
RVMD icon
Revolution Medicines
RVMD
+$40.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Miscellaneous 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYMR icon
1
Kymera Therapeutics
KYMR
$9.82B
$428M 14.41%
5,502,710
– –
RVMD icon
2
Revolution Medicines
RVMD
$44.6B
$267M 9%
3,356,782
-618,131
-16% -$40.5M
MLTX icon
3
MoonLake Immunotherapeutics
MLTX
$1.28B
$260M 8.76%
19,751,284
– –
GPCR icon
4
Structure Therapeutics
GPCR
$3.38B
$242M 8.15%
3,479,022
+275,105
+9% +$11.2M
OLMA icon
5
Olema Pharmaceuticals
OLMA
$899M
$132M 4.46%
5,295,893
– –
MIRM icon
6
Mirum Pharmaceuticals
MIRM
$5.94B
$118M 3.98%
1,495,290
– –
GHRS icon
7
GH Research
GHRS
$1.92B
$112M 3.77%
8,827,712
– –
XNCR icon
8
Xencor
XNCR
$1.94B
$109M 3.68%
7,133,720
+4,393,579
+160% +$65.6M
ZYME icon
9
Zymeworks
ZYME
$2.02B
$104M 3.49%
3,938,641
– –
PVLA
10
Palvella Therapeutics
PVLA
$2.16B
$92M 3.1%
879,009
-282,240
-24% -$24.1M
KURA icon
11
Kura Oncology
KURA
$1.13B
$89.5M 3.01%
8,617,162
– –
STOK icon
12
Stoke Therapeutics
STOK
$2.04B
$71.9M 2.42%
2,265,674
+608,578
+37% +$18.3M
XOMA
13
DELISTED
Xoma
XOMA
$68.9M 2.32%
2,590,303
– –
ABVX
14
Abivax
ABVX
$9.89B
$68.5M 2.31%
508,031
-50,000
-9% -$5.46M
NKTR icon
15
Nektar Therapeutics
NKTR
$2.48B
$65.9M 2.22%
1,559,595
+283,000
+22% +$15.8M
ACIU icon
16
AC Immune
ACIU
$263M
$62.2M 2.1%
19,822,436
– –
GLUE icon
17
Monte Rosa Therapeutics
GLUE
$1.14B
$60.1M 2.02%
3,835,886
-1,824,246
-32% -$24.6M
CGEM icon
18
Cullinan Oncology
CGEM
$1.4B
$59.5M 2%
5,750,683
– –
TYRA icon
19
Tyra Biosciences
TYRA
$1.49B
$55.9M 1.88%
2,127,665
-1,522,129
-42% -$28M
IRON icon
20
Disc Medicine
IRON
$3.07B
$51.6M 1.74%
+650,000
New +$54.9M
IMCR icon
21
Immunocore
IMCR
$1.89B
$50.3M 1.69%
1,488,975
-85,313
-5% -$3.01M
IVVD icon
22
Invivyd
IVVD
$284M
$48.2M 1.62%
+19,525,000
New +$40.6M
SEPN
23
Septerna Inc
SEPN
$1.82B
$48M 1.61%
1,720,782
-2,295,008
-57% -$54.8M
ANNX icon
24
Annexon
ANNX
$942M
$45.8M 1.54%
9,128,080
+2,128,080
+30% +$8.14M
CMPX icon
25
Compass Therapeutics
CMPX
$432M
$41.7M 1.4%
7,764,842
+3,014,842
+63% +$13.9M
1
2

Similar funds

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.91B AUM 14.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
AC
Anther Capital Hong Kong $3.91B AUM
FFGIM
Founders Fund Growth II Management San Francisco, California $3.9B AUM
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BVF Inc's Q4 2025 Portfolio in Review

As of Q4 2025, BVF Inc held 48 positions worth $2.97B, up 20% from $2.47B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

BVF Inc withdrew a net $339M in Q4 2025, closing 7 positions and reducing 8 holdings. Its most notable exit was Protagonist Therapeutics, an estimated $170M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, BVF Inc opened a new position in Disc Medicine worth $51.6M.

  • BVF Inc's largest Q4 2025 buy was Disc Medicine: 650,000 shares worth $51.6M.
  • BVF Inc added most to Xencor in Q4 2025, an estimated $65.6M increase.
  • BVF Inc's biggest Q4 2025 reduction was Axsome Therapeutics, cutting an estimated $61.6M.
  • BVF Inc fully exited Protagonist Therapeutics in Q4 2025, selling an estimated $170M.
  • BVF Inc's ten largest holdings make up 63% of its $2.97B portfolio in Q4 2025.
  • BVF Inc opened 2 new positions and closed 7 in Q4 2025.
  • BVF Inc's portfolio value rose 20% quarter-over-quarter to $2.97B.

Based on BVF Inc's 13F filing for Q4 2025, filed 17 Feb 2026.